keyword
MENU ▼
Read by QxMD icon Read
search

Ulipristal acetate

keyword
https://www.readbyqxmd.com/read/29752924/emergency-contraception-supply-in-australian-pharmacies-after-the-introduction-of-ulipristal-acetate-a-mystery-shopping-mixed-methods-study
#1
Jack Charles Collins, Carl Richard Schneider, Rebekah Jane Moles
OBJECTIVE: To explore the supply of emergency contraception (EC) from Australian community pharmacies after the introduction of ulipristal acetate (UPA), and to explore pharmacists' knowledge, decision-making, attitudes, and beliefs surrounding supplying EC. STUDY DESIGN: A mixed-methods approach of mystery shopping with structured interview was employed. From August-November 2017, 20 pharmacy students mystery-shopped 10 community pharmacies in metropolitan Sydney, Australia, requesting "the morning after pill"...
May 9, 2018: Contraception
https://www.readbyqxmd.com/read/29718788/vilaprisan-for-treating-uterine-fibroids
#2
Gian Benedetto Melis, Manuela Neri, Bruno Piras, Anna Maria Paoletti, Silvia Ajossa, Monica Pilloni, Maria Francesca Marotto, Valentina Corda, Alessandra Saba, Elena Giancane, Valerio Mais
Introduction The medical strategy to antagonize myoma size and related-symptoms is to reduce estrogen and progesterone activity on myomas. This can be obtained with the GnRH agonist (GnRHa) or with compounds that antagonize progesterone stimulatory activity on myomas. Selective progesterone receptor modulators (SPRMs) bind progesterone receptor (PR), leading to both agonist and antagonist effects. The result of SPRMs's action is tissue-specific and it depends on the particular affinity and strength of each SPRM...
May 2, 2018: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29709683/a-single-preovulatory-administration-of-ulipristal-acetate-affects-the-decidualization-process-of-the-human-endometrium-during-the-receptive-period-of-the-menstrual-cycle
#3
Saúl Lira-Albarrán, Marta Durand, David Barrera, Claudia Vega, Rocio García Becerra, Lorenza Díaz, Janice García-Quiroz, Claudia Rangel, Fernando Larrea
In order to get further information on the effects of ulipristal acetate (UPA) upon the process of decidualization of endometrium, a functional analysis of the differentially expressed genes in endometrium (DEG) from UPA treated-versus control-cycles of normal ovulatory women was performed. A list of 1183 endometrial DEG, from a previously published study by our group, was submitted to gene ontology, gene enrichment and ingenuity pathway analyses (IPA). This functional analysis showed that decidualization was a biological process overrepresented...
April 27, 2018: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/29706284/ulipristal-acetate-for-the-management-of-large-uterine-fibroids-associated-with-heavy-bleeding-a-review
#4
REVIEW
Jacques Donnez, Guillaume E Courtoy, Olivier Donnez, Marie-Madeleine Dolmans
Ulipristal acetate (UPA), a selective progesterone receptor modulator (SPRM), offers new therapeutic options for the clinical management of large uterine fibroids associated with heavy menstrual bleeding or with other moderate or severe symptoms (bulk symptoms, pelvic pain, decreased quality of life). SPRM are synthetic compounds that exert an agonist or antagonist effect on target tissues by their binding to progesterone receptors. UPA reduces fibroid size, controls bleeding in a high percentage of women and significantly improves quality of life...
April 21, 2018: Reproductive Biomedicine Online
https://www.readbyqxmd.com/read/29703808/esmya-ulipristal-acetate-safety-update
#5
(no author information available yet)
No abstract text is available yet for this article.
April 26, 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29626678/ulipristal-acetate-improves-clinical-symptoms-in-women-with-adenomyosis-and-uterine-fibroids
#6
Meritxell Gracia, Marta Alcalà, Janisse Ferreri, Mariona Rius, Cristina Ros, María Adela Saco, María Ángeles Martínez-Zamora, Francisco Carmona
STUDY OBJECTIVE: To study the effects of ulipristal acetate (UPA) on adenomyosis-associated clinical symptoms. DESIGN: A retrospective, single-center observational study. (Canadian Task Force Classification II-2). SETTING: A university tertiary referral center. PATIENTS: Premenopausal women (163) with adenomyosis and symptomatic uterine fibroids (41 patients, A+F group) versus a control group with only fibroids (122 patients, F group) treated with the first course of UPA...
April 4, 2018: Journal of Minimally Invasive Gynecology
https://www.readbyqxmd.com/read/29602142/predictive-factor-for-volume-reduction-of-uterine-fibroids-after-short-term-use-of-ulipristal-acetate
#7
Bo Seong Yun, Seok Ju Seong, Yong Wook Jung, Mi-La Kim, Hyo Sook Bae, Mi Kyoung Kim, Sung Shin Shim
OBJECTIVES: Ulipristal acetate (UPA) is a selective progesterone receptor modulator, which has been used to treat uterine fibroids. Many published reports about the outcomes indicate effective control of bleeding and reduction in the fibroid volume following both short- and long-term therapy. However, the reported volume reduction varies across different reports. Therefore, the purpose of this study was to investigate the factors that can affect the volume reduction of uterine fibroids, after short-term UPA therapy in patients with symptomatic uterine fibroids...
March 17, 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/29544204/two-synthetic-progestins-and-natural-progesterone-are-responsible-for-most-of-the-progestagenic-activities-in-municipal-wastewater-treatment-plant-effluents-in-the-czech-and-slovak-republics
#8
Pavel Šauer, Alžběta Stará, Oksana Golovko, Olga Valentová, Adam Bořík, Roman Grabic, Hana Kocour Kroupová
Vast numbers of xenobiotics are known still to be present in treated municipal wastewater treatment plant (WWTP) effluents. Some of these possess endocrine-disrupting potency and pose risks for exposed aquatic animals. We searched for 17 potential environmental contaminants having affinity to the progesterone receptor. Relative potency values of these progesterone receptor-active chemicals were obtained. On the basis of relative potencies and measured environmental concentrations, the contribution of progestins to measured progestagenic activities was evaluated...
June 15, 2018: Water Research
https://www.readbyqxmd.com/read/29526144/ulipristal-acetate-for-uterine-fibroids-2-years-of-real-world-experience-in-a-uk-hospital
#9
Natalie Woodhead, Rachel Pounds, Shirin Irani, Poonam Pradhan
Ulipristal acetate (UPA), is a selective progesterone-receptor modulator, it decreases fibroid size and reduces menstrual bleeding. We reviewed its use at the Heart of England Foundation Trust (HEFT), one of the largest prescribing trusts in the UK. The electronic records of patients treated with UPA from January 2013 to August 2015 were reviewed. One hundred and thirty four patients received UPA, 20 women (15%) received a second course. Eighty percent reported subjective global improvements in symptoms after the first course; 45...
March 12, 2018: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/29525690/ulipristal-acetate-decreases-transforming-growth-factor-%C3%AE-3-serum-and-tumor-tissue-concentrations-in-patients-with-uterine-fibroids
#10
Michał Ciebiera, Marta Włodarczyk, Małgorzata Wrzosek, Aneta Słabuszewska-Jóźwiak, Grażyna Nowicka, Grzegorz Jakiel
OBJECTIVE: To evaluate and compare transforming growth factor β3 (TGF-β3) serum concentration in patients with uterine fibroids (UFs) without hormone treatment, treated with ulipristal acetate (UPA), and controls; to evaluate TGF-β3 concentrations in UF tissue in patients without hormone treatment and those treated with UPA; and to evaluate the correlations of age and body mass index (BMI) with TGF-β3 serum and UF tissue levels between the groups. DESIGN: Retrospective cohort study...
March 2018: Fertility and Sterility
https://www.readbyqxmd.com/read/29498074/influence-of-ulipristal-acetate-therapy-on-uterine-fibroid-related-symptoms-and-on-uterine-and-fibroid-volumes-and-vascularity-indices-assessed-by-ultrasound
#11
Silvia Baggio, Paola Pomini, Fabiana Galeone, Francesca Presti, Lorenza Santi, Ricciarda Raffaelli, Massimo Franchi
OBJECTIVES: To investigate the modifications of uterine and fibroid volume, to study Doppler changes in uterine arteries and fibroid-supplying vessels, and to assess possible symptomatic relief after 3 months of treatment with ulipristal acetate. METHODS: Forty-two premenopausal women with symptomatic fibroids were included in the study. They were evaluated clinically for the symptoms reported and underwent ultrasound examinations before starting treatment and after 3 months of therapy with ulipristal acetate...
March 2, 2018: Journal of Ultrasound in Medicine: Official Journal of the American Institute of Ultrasound in Medicine
https://www.readbyqxmd.com/read/29486606/emerging-treatment-options-for-uterine-fibroids
#12
Jacques Donnez, Pablo Arriagada, Olivier Donnez, Marie-Madeleine Dolmans
Uterine fibroids (also known as leiomyomas or myomas) are the most common form of benign uterine tumors. Current management strategies involve mainly surgical interventions, but the choice of treatment is guided by patient age and desire to preserve fertility or avoid 'radical' surgery such as hysterectomy. Areas covered: There is growing evidence of the crucial role of progesterone pathways in the pathophysiology of uterine fibroids, leading to increasing use of selective progesterone receptor modulators (SPRMs) such as ulipristal acetate...
March 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29483856/ulipristal-acetate-as-a-treatment-option-for-uterine-fibroids
#13
REVIEW
Karolina Piecak, Paweł Milart, Ewa Woźniakowska, Tomasz Paszkowski
Uterine fibroids are the most common benign uterine tumours. Clinical symptoms include abnormal bleeding, pelvic pressure, pelvic pain, infertility and obstetric complications. Approximately one third of women with fibroids will require treatment. The management also depends on the number, size, and location of the fibroids. There are surgical and non-surgical treatment options. The choice of therapy depends on different factors, such as the severity of symptoms, tumour characteristics, age, and wish to preserve the uterus and fertility...
December 2017: Przeglad Menopauzalny, Menopause Review
https://www.readbyqxmd.com/read/29453736/reproductive-epidemiology-of-glial-tumors-may-reveal-novel-treatments-high-dose-progestins-or-progesterone-antagonists-as-endocrino-immune-modifiers-against-glioma
#14
REVIEW
Meric A Altinoz, Aysel Ozpinar, Ilhan Elmaci
Female gender, contraceptives, and menopausal hormone replacement treatments containing progesterone analogues associate with higher risk of meningiomas yet with lower risk of gliomas. Progesterone receptor (PR) expression and mifepristone treatment was highly discussed for meningiomas. However, much less is known in regard to progesterone actions in gliomas despite PR expression strongly correlates with their grade. Meningiomas and gliomas may grow faster during gestation; but paradoxically, parousity reduces lifetime risk of gliomas which can be explained with dichotomous cell growth-stimulating and inhibitory actions of progesterone at low versus high levels...
February 17, 2018: Neurosurgical Review
https://www.readbyqxmd.com/read/29420395/ulipristal-acetate-for-treatment-of-symptomatic-uterine-leiomyomas-a-randomized-controlled-trial
#15
James A Simon, William Catherino, James H Segars, Rick E Blakesley, Anna Chan, Vilma Sniukiene, Ayman Al-Hendy
OBJECTIVE: To assess efficacy and tolerability of ulipristal acetate, a selective progesterone receptor modulator, for treatment of symptomatic uterine leiomyomas. METHODS: This phase 3, double-blind, placebo-controlled study enrolled premenopausal women (aged 18-50 years) with abnormal uterine bleeding, one or more discrete leiomyomas, and uterine size 20 weeks of gestation or less. Patients were randomized 1:1:1 to 5 mg ulipristal, 10 mg ulipristal, or placebo once daily for 12 weeks followed by 12-week drug-free follow-up...
March 2018: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29409847/cost-effectiveness-of-emergency-contraception-options-over-1-year
#16
Brandon K Bellows, Casey R Tak, Jessica N Sanders, David K Turok, Eleanor B Schwarz
BACKGROUND: The copper intrauterine device is the most effective form of emergency contraception and can also provide long-term contraception. The levonorgestrel intrauterine device has also been studied in combination with oral levonorgestrel for women seeking emergency contraception. However, intrauterine devices have higher up-front costs than oral methods, such as ulipristal acetate and levonorgestrel. Health care payers and decision makers (eg, health care insurers, government programs) with financial constraints must determine if the increased effectiveness of intrauterine device emergency contraception methods are worth the additional costs...
May 2018: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29408988/matrix-metalloproteinase-activity-correlates-with-uterine-myoma-volume-reduction-after-ulipristal-acetate-treatment
#17
Guillaume E Courtoy, Patrick Henriet, Etienne Marbaix, Matthieu de Codt, Mathieu Luyckx, Jacques Donnez, Marie-Madeleine Dolmans
Context: Ulipristal acetate (UPA), a selective progesterone receptor modulator, clinically reduces uterine myoma size in 80% of cases. However, the molecular mechanism of action is still poorly understood, as is the reason why 20% of myomas do not respond to treatment. Objective: To elucidate whether matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) are associated with myoma volume shrinkage after UPA therapy. Design: Prospective study...
February 1, 2018: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29408752/ulipristal-acetate-for-pre-operative-management-of-uterine-fibroids-modeling-outcomes-and-costs
#18
Brigitta Badiani, Marco Chiumente, Andrea Messori
OBJECTIVES: The aim of this study was to evaluate the pharmacoeconomic profile in Italy of preoperative treatment with ulipristal acetate at the dose of 5 mg/day for 13 weeks in comparison with placebo prior to surgical management of symptomatic uterine fibroids. STUDY DESIGN: The pharmacoeconomic analysis was based on the calculation of incremental cost-effectiveness ratio (ICER). Effectiveness data were derived from the randomized-controlled trial PEARL-1, whilst costs data were retrieved from the published literature...
March 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/29398236/acute-bilateral-serous-central-chorioretinopathy-after-emergency-contraceptive-therapy-with-ulipristal-acetate
#19
J C Molina Martín, M Balboa Alonso, J García Sánchez, M González Herrera, J R Hueso Abancens, E Mengual Verdú
CASE REPORT: The case concerns a 31 year-old woman with no previous history who consulted due to decreased vision in both eyes. She mentioned taking 1 pill of ulipristal acetate (30mg) as an emergency contraceptive four days before the visual symptoms appeared. In the examination, a better corrected visual acuity of 0.6 was found in the right eye and 0.8 in left eye (by Snellen chart), and bilateral macular serous detachment. It was decided to observe, and 15 days later she showed a functional and anatomical improvement...
February 1, 2018: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/29338440/selective-progesterone-receptor-modulators-current-applications-and-perspectives
#20
N Chabbert-Buffet, K Kolanska, E Daraï, P Bouchard
Selective progesterone receptor modulators (SPRMs) are steroid progesterone receptor ligands able to induce agonistic or antagonistic activities. Mifepristone, the class leader, was primarily used for pregnancy termination from the 1980s. Emergency contraception with extended activity was the second major development 30 years later, with mifepristone in some countries and ulipristal acetate world-wide. More recently, ulipristal acetate was released for the treatment of myoma-related uterine bleeding. In addition to a very rapid cessation of bleeding, SPRMs allow a decrease in myoma volume, as do gonadotropin releasing hormone analogs...
January 17, 2018: Climacteric: the Journal of the International Menopause Society
keyword
keyword
119605
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"